Core Insights - Transgene announced a 30-minute oral presentation on TG4050, an Individualized Neoantigen Therapeutic Vaccine, at the World Vaccine Congress from March 31 to April 2, 2026, in Washington, D.C. [1] - The presentation will focus on findings from the Phase 1 part of the ongoing Phase 1/2 trial in head and neck cancer, discussing the potential of individualized neoantigen vaccines to transform early-stage cancer treatment [2][3] Company Overview - Transgene is a biotechnology company specializing in the design and development of virus-based immunotherapies for cancer treatment, with TG4050 being its lead asset [5] - The company utilizes the myvac® platform to create individualized therapeutic vaccines tailored to each patient's tumor characteristics, supported by AI technology from its partner NEC [7] Clinical Trial Insights - In the Phase 1 trial, patients with resected head and neck cancer treated with TG4050 developed new immune responses targeting specific neoantigens, with all treated patients remaining tumor-free two years post-treatment [3] - Transgene aims to continue generating clinical data for head and neck cancer and other indications to prevent cancer relapse in at-risk patients [4]